ReviewPharmacology & therapeutics2007
Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
Review in Pharmacology & therapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03192995 (Treatment With Lorcaserin for Cocaine Use), which is not on this map. Cited by 259 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment With Lorcaserin for Cocaine Use: The TLC Study
Who cites it
259 citing papers in PubMed, 2 syntheses or guidelines pooled it, 642 citations in OpenAlex.
- Serotonergic gene variation in substance use pharmacotherapy: a systematic review.Pharmacogenomics · 2015Pooled it
- Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.Alimentary pharmacology & therapeutics · 2012Pooled it
- Bayesian Population Pharmacokinetic Modeling of Ondansetron for Neonatal Opioid Withdrawal Syndrome.Clinical and translational science · 2025Trial
- Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder.Drug and alcohol dependence · 2024Trial
- Trial
- Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Trial
- Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Trial
- Selective Serotonin Reuptake Inhibitor-Associated Bruxism: Neuropharmacologic Mechanisms and Clinical Implications.Cureus · 2026Review
- Effects of oxycodone on tonic levels and phasic release of serotonin in the rat nucleus accumbens core.Bioelectrochemistry (Amsterdam, Netherlands) · 2026Article
- Transcranial direct current stimulation and lesions hierarchically reorganize brain network dynamics with biological annotations.Fundamental research · 2026Article
- Psilocybin modulates social behaviour in male and female mice in a time-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Attenuation of cue-induced heroin-seeking by the atypical antidepressant mirtazapine.Drug and alcohol dependence reports · 2026Article
- Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders.Journal of medicinal chemistry · 2026Review
- Cell Signaling by Tryptophan Catabolism.Biochemistry · 2026Review
- AI-derived therapeutic development of a serotonin receptor-targeting drug for the treatment of opioid use disorder.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Physical Activity and Depressive Mood Share the Structural Connectivity Between Motor and Reward Networks.Neuroscience bulletin · 2026Article
- Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain.Scientific reports · 2026Article
- Neurochemical and Neurophysiological Effects of Intravenous Administration ofThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Modulation of stress and neuroplasticity biomarkers via rhythmic vocalization: a controlled study on NDNF, cortisol, and monoamines.BMC neuroscience · 2026Article
- Emotional Blunting in Hong Kong Patients with Major Depressive Disorder Treated with Vortioxetine: A Naturalistic Observational Study.Biomedicines · 2026Article
199 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The neurotransmitter dopamine (DA) has a long association with normal functions such as motor control, cognition, and reward, as well as a number of syndromes including drug abuse, schizophrenia, and Parkinson's disease. Studies show that serotonin (5-HT) acts through several 5-HT receptors in the brain to modulate DA neurons in all 3 major dopaminergic pathways. There are at least fourteen 5-HT receptor subtypes, many of which have been shown to play some role in mediating 5-HT/DA interactions. Several subtypes, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 and 5-HT4 receptors, act to facilitate DA release, while the 5-HT2C receptor mediates an inhibitory effect of 5-HT on DA release. Most 5-HT receptor subtypes only modulate DA release when 5-HT and/or DA neurons are stimulated, but the 5-HT2C receptor, characterized by high levels of constitutive activity, inhibits tonic as well as evoked DA release. This review summarizes the anatomical evidence for the presence of each 5-HT receptor subtype in dopaminergic regions of the brain and the neuropharmacological evidence demonstrating regulation of each DA pathway. The relevance of 5-HT receptor modulation of DA systems to the development of therapeutics used to treat schizophrenia, depression, and drug abuse is discussed. Lastly, areas are highlighted in which future research would be maximally beneficial to the treatment of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.